Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for women's cancers, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for women's cancers, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Wednesday, September 4, 2024, at 7:45 a.m. ET at the Marriott Marquis in New York, NY.
The company's management team will engage in a Fireside Chat format discussion. Investors and interested parties can access a live webcast of the chat through the News & Events section of Olema's investor relations website at ir.olema.com. The webcast will remain archived for at least 30 days after the event, providing an opportunity for those unable to attend live to catch up on the discussion.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was +1.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conference:
Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Wednesday, September 4, 2024, at 7:45 a.m. ET
Location: Marriott Marquis in New York, NY
Format: Fireside Chat
A live webcast of the Fireside Chat will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:
Geoffrey Mogilner, Investor Relations and Communications
ir@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.